| Drug Name | GPCR-targeted Project 019 |
| Description |
Frizzled homologue 10 (FZD10) is a member of the Frizzled family and acts as a receptor for Wnt proteins. FZD10 has shown to be upregulated in cancer types such as colorectal cancer, gastric cancer, and synovial sarcoma, but is not present in normal human organs. |
| Target | Frizzled homologue 10 (FZD10) |
| Drug Modality | Monoclonal antibody |
| Indication | Cancers |
| Product Category | Biologic |
| Mechanism of Action | Wnt signaling pathway inhibitors |
| Status | Preclinical |
| Patent | Granted |
We look forward to hearing from you.
Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.
 |
Protheragen Inc. |
 |
Quick Links |